サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1419003

欧州の遺伝子融合検査市場 - 分析と予測（2023年～2033年）

Europe Gene Fusion Testing Market: Analysis and Forecast, 2023-2033

出版日
発行
BIS Research
ページ情報
英文 83 Pages
納期
1～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
欧州の遺伝子融合検査市場 - 分析と予測（2023年～2033年）
出版日: 2024年01月31日
発行: BIS Research
ページ情報: 英文 83 Pages
納期: 1～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

欧州の遺伝子融合検査の市場規模は、2023年に7,140万米ドルと評価され、2033年には2億4,820万米ドルに達すると予測されており、予測期間の2023年～2033年のCAGRは13.27%になると見込まれています。

遺伝子融合検査市場は、標的治療の進歩のために遺伝子融合検査の利用が増加していることから、成長が見込まれています。

主要市場統計
予測期間 2023年～2033年
2023年評価 7,140万米ドル
2033年予測 2億4,820万米ドル
CAGR 13.27%

欧州の遺伝子融合検査市場は著しい成長と進化を遂げています。この背景には、同地域が精密医療や標的療法の開発にますます力を入れていることなど、いくつかの要因があります。遺伝子融合検査は、特定の疾患を引き起こす遺伝子の変化を特定するものであり、個々の患者に合わせた治療を行う上で極めて重要な役割を果たしています。ヘルスケアの革新と研究に対する欧州のコミットメントが、遺伝子融合検査技術の進歩を促進し、より利用しやすく正確なものにしています。さらに、同地域の強力な製薬・バイオテクノロジー部門は、新規治療薬の開発を目指し、これらの検査に対する需要を促進しています。

さらに、規制当局の支援や研究機関と業界関係者との協力関係も市場拡大に寄与しています。欧州では個別化医療と分子診断が引き続き重視されているため、同地域の遺伝子融合検査市場は継続的な成長と革新が見込まれています。

当レポートでは、欧州の遺伝子融合検査市場について調査し、市場の概要とともに、適応症別、国別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

エグゼクティブサマリー

第1章 市場の範囲

第2章 調査手法

第3章 市場概要

  • 遺伝子融合検査のイントロダクション
  • 関係者のアンケート回答

第4章 業界の展望

  • 規制状況
    • 欧州の法的要件と枠組み

第5章 遺伝子融合検査市場（地域別）、金額（100万米ドル）、2022年～2033年

  • 概要
  • 欧州
    • 欧州の遺伝子融合検査市場、適応症別
    • 欧州の遺伝子融合検査市場、国別

第6章 市場-競合ベンチマーキングと企業プロファイル

  • 概要
  • Biocartis
  • F. Hoffmann-La Roche Ltd
  • OncoDNA
  • OncoDNA
図表

List of Figures

  • Figure 1: Europe Gene Fusion Testing Market, $Million, 2022-2033
  • Figure 2: Europe Gene Fusion Testing Market: Drivers, Restraints, and Opportunities
  • Figure 3: Europe Gene Fusion Testing Market (by Indication), $Million, 2022-2033
  • Figure 4: Europe Gene Fusion Testing Market: Research Methodology
  • Figure 5: Primary Research Methodology
  • Figure 6: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 7: Top-Down Approach (Segment-Wise Analysis)
  • Figure 8: Different Approaches to Study Gene Fusion
  • Figure 9: Different Techniques Used in Gene Fusion Testing
  • Figure 10: Europe Gene Fusion Testing Market, $Million, 2022-2033
  • Figure 11: Artificial Intelligence and Machine Learning in Gene Fusion Testing
  • Figure 12: SOPHiA DDM RNAtarget Technology Workflow
  • Figure 13: Awareness to the Concept of Gene Fusion Testing
  • Figure 14: Familarity with NGS Offerings by Key Market Players for Gene Fusion Testing
  • Figure 15: Perceived Importance of Key Drivers to Improve Gene Fusion Testing Adoption
  • Figure 16: Agreement Level with Key Barriers to Gene Fusion Testing Adoption
  • Figure 17: Europe In Vitro Diagnostic Devices Regulation Regulatory Process
  • Figure 18: Gene Fusion Testing Market (by Region), $Million, 2022 and 2033
  • Figure 19: Europe Gene Fusion Testing Market, $Million, 2022-2033
  • Figure 20: Europe: Market Dynamics
  • Figure 21: Europe Gene Fusion Testing Market (by Indication), $Million, 2022-2033
  • Figure 22: Europe Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
  • Figure 23: Germany Gene Fusion Testing Market, $Million, 2022-2033
  • Figure 24: Germany Gene Fusion Testing Market (by Indication), $Million, 2022-2033
  • Figure 25: Germany Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
  • Figure 26: France Gene Fusion Testing Market, $Million, 2022-2033
  • Figure 27: France Gene Fusion Testing Market (by Indication), $Million, 2022-2033
  • Figure 28: France Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
  • Figure 29: U.K. Gene Fusion Testing Market, $Million, 2022-2033
  • Figure 30: U.K. Gene Fusion Testing Market (by Indication), $Million, 2022-2033
  • Figure 31: U.K. Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
  • Figure 32: Italy Gene Fusion Testing Market, $Million, 2022-2033
  • Figure 33: Italy Gene Fusion Testing Market (by Indication), $Million, 2022-2033
  • Figure 34: Italy Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
  • Figure 35: Spain Gene Fusion Testing Market, $Million, 2022-2033
  • Figure 36: Spain Gene Fusion Testing Market (by Indication), $Million, 2022-2033
  • Figure 37: Spain Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
  • Figure 38: Netherlands Gene Fusion Testing Market, $Million, 2022-2033
  • Figure 39: Netherlands Gene Fusion Testing Market (by Indication), $Million, 2022-2033
  • Figure 40: Netherlands Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
  • Figure 41: Rest-of-Europe Gene Fusion Testing Market, $Million, 2022-2033
  • Figure 42: Rest-of-Europe Gene Fusion Testing Market (by Indication), $Million, 2022-2033
  • Figure 43: Rest-of-Europe Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
  • Figure 44: Gene Fusion Testing Market (by Total Number of Companies Profiled)
  • Figure 45: Biocartis: Product Portfolio
  • Figure 46: Biocartis: Overall Financials, $Million, 2020-2022
  • Figure 47: Biocartis: Revenue (by Segment), $Million, 2020-2022
  • Figure 48: Biocartis: Revenue (by Region), $Million, 2020-2022
  • Figure 49: Biocartis: R&D Expenditure, $Million, 2020-2022
  • Figure 50: F. Hoffmann-La Roche Ltd: Product Portfolio
  • Figure 51: F. Hoffmann-La Roche Ltd: Product Portfolio
  • Figure 52: F. Hoffmann-La Roche Ltd: Overall Financials, 2020-2022
  • Figure 53: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2020-2022
  • Figure 54: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2020-2022
  • Figure 55: OncoDNA: Product Portfolio
  • Figure 56: QIAGEN N.V.: Product Portfolio
  • Figure 57: QIAGEN N.V.: Overall Financials, $Million, 2020-2022
  • Figure 58: QIAGEN N.V.: Revenue (by Segment), $Million, 2020-2022
  • Figure 59: QIAGEN N.V.: Revenue (by Region), $Million, 2020-2022
  • Figure 60: QIAGEN N.V.: R&D Expenditure, $Million, 2020-2022

List of Tables

  • Table 1: Europe Gene Fusion Testing Market, Impact Analysis
  • Table 2: Key Questions Answered in the Report
  • Table 3: Advantages of Gene Fusion Testing
  • Table 4: Limitations of Gene Fusion Testing
  • Table 5: NTRK Gene Fusion in Different Types of Cancer
  • Table 6: Different Types of Gene Fusion
  • Table 7: Gene Fusion Testing Market: Regulatory Scenario
  • Table 8: NTRK Test Rate Across Several Europen Countries
目次
Product Code: BHP1840SS

“The Europe Gene Fusion Testing Market Expected to Reach $248.2 Million by 2033.”

Introduction to Europe Gene Fusion Testing Market

The Europe gene fusion testing market was valued at $71.4 million in 2023 and is anticipated to reach $248.2 million by 2033, witnessing a CAGR of 13.27% during the forecast period 2023-2033. The gene fusion testing market is anticipated to experience growth due to the increasing use of gene fusion testing for the advancement of targeted therapies.

KEY MARKET STATISTICS
Forecast Period2023 - 2033
2023 Evaluation$71.4 Million
2033 Forecast$248.2 Million
CAGR13.27%

Market Introduction

The gene fusion testing market in Europe is experiencing significant growth and evolution. This can be attributed to several factors, including the region's increasing focus on precision medicine and the development of targeted therapies. Gene fusion testing, which involves identifying genetic alterations that drive certain diseases, plays a pivotal role in tailoring treatments to individual patients. Europe's commitment to healthcare innovation and research is fostering advancements in gene fusion testing technologies, making them more accessible and accurate. Additionally, the region's strong pharmaceutical and biotechnology sectors are driving demand for these tests as they seek to develop novel therapeutics.

Furthermore, regulatory support and collaborations between research institutions and industry players are contributing to market expansion. As Europe continues to emphasize personalized medicine and molecular diagnostics, the gene fusion testing market in the region is poised for continued growth and innovation.

Market Segmentation:

Segmentation 1: by Indication

  • Solid Tumors
  • Hematological Malignancies

Segmentation 2: by Country

  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest-of-Europe

How can this report add value to an organization?

Workflow/Innovation Strategy: The Europe gene fusion testing market (by indication) has been segmented into solid tumors and hematological malignancies. Moreover, the study provides the reader with a detailed understanding of the different indication of gene fusion testing in solid tumors.

Growth/Marketing Strategy: Gene fusion testing is a molecular diagnostic method employed to identify and analyze distinct genetic alterations in cancer cells. It arises when two distinct genes, typically from different chromosomes, abnormally join together, giving rise to a hybrid gene that generates a unique protein with modified functions.

Competitive Strategy: Key players in the Europe gene fusion testing market have been analyzed and profiled in the study, including manufacturers. Moreover, a detailed competitive benchmarking of the players operating in the Europe gene fusion testing market has been done to help the reader understand how players stack against each other, presenting a clear market landscape.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and regional presence.

Some of the prominent names in this market are:

  • Biocartis
  • F. Hoffmann-La Roche Ltd.
  • OncoDNA
  • QIAGEN N.V.

Table of Contents

Executive Summary

1. Market Scope

  • 1.1. Key Questions Answered in the Report

2. Research Methodology

3. Market Overview

  • 3.1. Introduction to Gene Fusion Testing
    • 3.1.1. Different Technologies for Gene Fusion Testing
    • 3.1.2. Advantages and Limitations of Gene Fusion Testing
    • 3.1.3. Current Market Size and Future Growth Potential, $Million, 2022-2033
      • 3.1.3.1. Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion vs. Other Gene Fusions
    • 3.1.4. Role of Artificial Intelligence (AI) and Machine Learning (ML) in Gene Fusion Testing
    • 3.1.5. Reimbursement Landscape
  • 3.2. Stakeholder's Survey Response
    • 3.2.1. Awareness of Gene Fusion Testing
    • 3.2.2. Familiarity with the NGS Offerings of the Following Companies
    • 3.2.3. Adoption and Barriers for Gene Fusion Testing

4. Industry Outlook

  • 4.1. Regulatory Landscape
    • 4.1.1. Legal Requirements and Frameworks in Europe

5. Gene Fusion Testing Market (by Region), Value ($Million), 2022-2033

  • 5.1. Overview
  • 5.2. Europe
    • 5.2.1. Europe Gene Fusion Testing Market, by Indication
    • 5.2.2. Europe Gene Fusion Testing Market (by Country)
      • 5.2.2.1. Germany
        • 5.2.2.1.1. Germany Gene Fusion Testing Market (by Indication)
      • 5.2.2.2. France
        • 5.2.2.2.1. France Gene Fusion Testing Market (by Indication)
      • 5.2.2.3. U.K.
        • 5.2.2.3.1. U.K. Gene Fusion Testing Market (by Indication)
      • 5.2.2.4. Italy
        • 5.2.2.4.1. Italy Gene Fusion Testing Market (by Indication)
      • 5.2.2.5. Spain
        • 5.2.2.5.1. Spain Gene Fusion Testing Market (by Indication)
      • 5.2.2.6. Netherlands
        • 5.2.2.6.1. Netherlands Gene Fusion Testing Market (by Indication)
      • 5.2.2.7. Rest-of-Europe
        • 5.2.2.7.1. Rest-of-Europe Gene Fusion Testing Market (by Indication)

6. Markets - Competitive Benchmarking & Company Profiles

  • 6.1. Overview
  • 6.2. Biocartis
    • 6.2.1. Company Overview
    • 6.2.2. Role of Biocartis in the Gene Fusion Testing Market
    • 6.2.3. Key Competitors
    • 6.2.4. Recent Developments
    • 6.2.5. Financials
    • 6.2.6. Key Insights about the Financial Health of the Company
    • 6.2.7. Analyst Perspective
  • 6.3. F. Hoffmann-La Roche Ltd.
    • 6.3.1. Company Overview
    • 6.3.2. Role of F. Hoffmann-La Roche Ltd in the Gene Fusion Testing Market
    • 6.3.3. Key Competitors
    • 6.3.4. Recent Developments
    • 6.3.5. Financials
    • 6.3.6. Key Insights about the Financial Health of the Company
    • 6.3.7. Analyst Perspective
  • 6.4. OncoDNA
    • 6.4.1. Company Overview
    • 6.4.2. Role of OncoDNA in the Gene Fusion Testing Market
    • 6.4.3. Key Competitors
    • 6.4.4. Recent Developments
    • 6.4.5. Analyst Perspective
  • 6.5. QIAGEN N.V.
    • 6.5.1. Company Overview
    • 6.5.2. Role of QIAGEN N.V. in the Gene Fusion Testing Market
    • 6.5.3. Key Competitors
    • 6.5.4. Recent Developments
    • 6.5.5. Financials
    • 6.5.6. Key Insights about the Financial Health of the Company
    • 6.5.7. Analyst Perspective